EUVIMEDObjevte EUVIMED
VergleichsstudieNetzwerk-MetaanalyseSystematische Übersicht

Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease

Mohammad Shehab iD, Fatema Alrashed, Abdulrahman Alrashidi, Amro Hassan, Christopher Ma iD, Neeraj Narula iD, Vipul Jairat iD, Miguel Regueiro iD, Talat Bessissow

Alimentary Pharmacology & Therapeutics · 2025-09 · 62 (5) · 472-482

DOI: 10.1111/apt.70295 ↗

At a glance

Vergleichsstudie in Alimentary Pharmacology & Therapeutics, published online on 2025-07-27. Written by Mohammad Shehab and 8 co-authors. Institution: Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer, University Hospital, Kuwait. Major MEDLINE topics: Biological Products, Crohn Disease. Cited 17 times so far (Crossref); 61 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Advances in medical management of Crohn's disease (CD) have transformed therapeutic goals. Clinical and endoscopic remission are important endpoints.

Aim

To compare the efficacy of different advanced therapies in patients with CD.

Methods

We performed a literature search up to January 2025. We included phase 3 randomised controlled trials (RCTs) against placebo or an active comparator. The primary endpoint was induction and maintenance of clinical remission (CD Activity Index [CDAI] < 150 points). Secondary endpoints included induction and maintenance of endoscopic remission (Simple Endoscopic Score for CD (SES‐CD) of ≤ 4 or CD Endoscopic Index of Severity (CDEIS) of ≤ 4). We performed network meta‐analysis (NMA) using the Frequentist method.

Results

We included 39 studies. Induction of clinical remission analysis showed that infliximab combination with azathioprine ranked highest (93.2%), followed by guselkumab (88.6%) and adalimumab (76.9%). Guselkumab was superior to most interventions in inducing clinical remission. In maintenance of clinical remission, combination of infliximab and azathioprine ranked highest (75.7%) followed by mirikizumab (71.8%) and guselkumab (71.5%). There was no statistically significant difference between therapies in maintaining clinical remission. In induction of endoscopic remission, upadacitinib (88.5%) ranked highest, followed by risankizumab (73.7%) and guselkumab (73.4%). Guselkumab (74%) ranked highest in maintaining endoscopic remission, followed by adalimumab (67%) and mirikizumab (64%).

Conclusion

Novel IL‐23 inhibitors (such as mirikizumab, risankizumab and guselkumab) and anti‐TNFs (such as infliximab and adalimumab) ranked high in the induction of clinical and endoscopic remission. This highlights the potential of novel advanced therapies for CD.

Subjects

MeSH terms (MEDLINE)

Biological ProductsCrohn DiseaseHumansAdalimumabAntibodies, Monoclonal, HumanizedDrug Therapy, CombinationInfliximabMaintenance ChemotherapyRandomized Controlled Trials as TopicRemission InductionTreatment Outcome

Author keywords

biologicsclinical remissioncrohn's diseaseendoscopic remissionsmall molecules

Substances

AdalimumabAntibodies, Monoclonal, HumanizedBiological ProductsguselkumabInfliximab

Authors and institutions

  • Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer, University Hospital, Kuwait.
  • Department of Medicine, College of Medicine and Health Sciences, Abdullah Al Salem University, Kuwait.
  • Division of Gastroenterology and Hepatology, Department of Medicine, McGill University Health Center, Montreal, Canada.
  • Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Jabriya, Kuwait.
  • Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada.
  • Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

ORCID profiles: Mohammad Shehab, Christopher Ma, Neeraj Narula, Vipul Jairat, Miguel Regueiro

Cite

APA

Shehab, M., Alrashed, F., Alrashidi, A., Hassan, A., Ma, C., Narula, N., Jairat, V., Regueiro, M., & Bessissow, T. (2025). Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. Alimentary Pharmacology & Therapeutics, 62(5), 472-482. https://doi.org/10.1111/apt.70295

Vancouver

Shehab M, Alrashed F, Alrashidi A, Hassan A, Ma C, Narula N, et al. Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. Alimentary Pharmacology & Therapeutics. 2025;62(5):472-482. doi:10.1111/apt.70295

BibTeX
@article{Shehab2025,
  author = {Shehab, Mohammad and Alrashed, Fatema and Alrashidi, Abdulrahman and Hassan, Amro and Ma, Christopher and Narula, Neeraj and Jairat, Vipul and Regueiro, Miguel and Bessissow, Talat},
  title = {Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {62},
  number = {5},
  pages = {472--482},
  doi = {10.1111/apt.70295}
}
Start for free →